Why Is Novo Nordisk Stock Falling On Friday? – Novo Nordisk (NYSE:NVO)
Friday, Novo Nordisk A/S NVO announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. for $1.075 billion, announced in August 2023. Also Read: European Drug Agency Supports Novo Nordisk’s Blockbuster Weight-Loss Drug … Read more
